Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15473291 | 0.93 | TSHR (0.63) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL14874503 | 0.86 | MEN1 (0.57) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL13175212 | 0.84 | CYP2D6 (0.56) | HSD17B10CYP2D6CYP2C9CYP2C19TAAR1 | |
| SCHEMBL13775217 | 0.83 | HRH3 (0.52) | TSHRHSD17B10CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL18697659 | 0.81 | TSHR (0.57) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL24885675 | 0.80 | ALDH1A1 (0.55) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL12772089 | 0.79 | TAS2R14 (0.50) | TSHRHTTALDH1A1KDM4ECYP2D6 | |
| SCHEMBL12772084 | 0.79 | TAAR1 (0.48) | TSHRKDM4EHPGDMAPK1CYP2D6 | |
| SCHEMBL14544445 | 0.78 | HTT (0.57) | TSHRHSD17B10MEN1KMT2AHTT | |
| SCHEMBL807255 | 0.78 | HSD17B10 (0.50) | TSHRHSD17B10MEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | GILEAD SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2023-04-27 | — | — | US | disclosed |
| WO-2022098371-A1 | PRODRUGS OF 1'-SUBSTITUTED CARBA-NUCLEOSIDE ANALOGUES FOR ANTIVIRAL TREATMENT | YAN MATTHEW (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021154687-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | GILEAD SCIENCES, INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-03-04 | — | — | US | disclosed |
| EP-3785717-A1 | METHODS FOR TREATING CORONAVIRIDAE INFECTIONS | Gilead Sciences, Inc. (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | GILEAD SCIENCES, INC. (US) | 2020-06-30 | — | — | US | disclosed |
| EP-3539546-A1 | PHOSPHONATE ANALOGS OF HIV INHIBITOR COMPOUNDS | Gilead Sciences, Inc. (US) | 2019-09-18 | — | — | EP | disclosed |
| US-20070078081-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-04-05 | — | — | US | disclosed |
| US-20070072809-A1 | Antiviral compounds | GILEAD SCIENCES, INC. | 2007-03-29 | — | — | US | disclosed |
| WO-2006110157-A9 | NUCLEOSIDE PHOSPHONATE CONJUGATES AS ANTI HIV AGENTS | GILEAD SCIENCES INC (US) | 2007-03-08 | — | — | WO | disclosed |
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | GILEAD SCIENCES, INC. | 2007-03-01 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| WO-2007014352-A2 | ANTIVIRAL PHOSPHONATE CONJUGATES FOR INHIBITION OF HIV | GILEAD SCIENCES, INC. (US) | 2007-02-01 | — | — | WO | disclosed |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | GILEAD SCIENCES INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | GILEAD SCIENCES, INC. | 2007-02-01 | — | — | US | disclosed |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | GILEAD SCIENCES, INC. | 2007-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049754-A1 | phosphorus substituted viricides such as ethyl (2S)-2-[[[(2R,5R)-5-(6-aminopurin-9-yl)-4-fluoro-2,5-dihydrofuran-2-yl]oxymethyl-phenoxyphosphoryl]amino]propanoate, used for treating or reducing a risk of human immunodeficiency virus (HIV) infection in a patient that may be exposed to HIV | INPP5D, INPPL1, MTAP | TSHR 4831/4885HSD17B10 4027/4885MEN1 4683/4885 |
| US-20210061806-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TSHR 3767/4885HSD17B10 3590/4885MEN1 3156/4885 |
| US-20070072809-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TSHR 4829/4885HSD17B10 2778/4885MEN1 4774/4885 |
| US-10695361-B2 | Methods for treating arenaviridae and coronaviridae virus infections | ACE, PNP, ACE2 | TSHR 4652/4885HSD17B10 1313/4885MEN1 4132/4885 |
| US-20070027116-A1 | Therapeutic phosphonate derivatives | PPP5C, PPP3CA, PPP4R3A | TSHR 3549/4885HSD17B10 3814/4885MEN1 2037/4885 |
| US-20230125751-A1 | METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS | PNP, RPIA, HPRT1 | TSHR 3767/4885HSD17B10 3590/4885MEN1 3156/4885 |
| US-20070078081-A1 | Antiviral compounds | MAVS, EIF2AK2, ZC3HAV1 | TSHR 4825/4885HSD17B10 2717/4885MEN1 4777/4885 |
| US-20070027114-A1 | Phosphonate analogs of antimetabolites | TYMP, PHOSPHO1, PHPT1 | TSHR 2471/4885HSD17B10 4069/4885MEN1 208/4885 |
| US-11660307-B2 | Methods for treating SARS CoV-2 infections | ACE2, ACE, PNP | TSHR 4227/4885HSD17B10 672/4885MEN1 3432/4885 |
| US-20230346812-A1 | METHODS FOR TREATING SARS COV-2 INFECTIONS | ACE2, ACE, PNP | TSHR 4227/4885HSD17B10 672/4885MEN1 3432/4885 |
| US-20070010489-A1 | Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds | PPA1, PNP, PPME1 | TSHR 4782/4885HSD17B10 1703/4885MEN1 3990/4885 |
| US-20070027113-A1 | Purine nucleoside phosphorylase inhibitory phosphonate compounds | PNP, TYMP, MTAP | TSHR 4517/4885HSD17B10 2868/4885MEN1 3116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.